CAS 66357-59-3 Ranitidine Hydrochloride - Analytical Products / Alfa Chemistry

CAT	APS66357593
CAS	66357-59-3
Structure
MDL Number	MFCD00069339
Synonyms	Ultidine, Microtid, Vizerul, Normon, Quicran, Gastridin, Rantacid, Ul-Pep, Ultac, Ulceran, Ratic, Rosimol, Terposen, Ptinolin, Ranin, Atural, Axoban, Ulcirex, Ranisen, Acidex, Eltidine, Anistal, Zintac, RND, Zantadin, Ranitidine hydrochloride, 1,1-Ethenediamine, N-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N'-methyl-2-nitro-, monohydrochloride (9CI), Gastrial, Vesyca, Zantab, Curan,Ranitidine Hydrochloride, Noctone, Ulcex, Urantac, Weidos, Rantidol, Taural, Ulceranin, Apo-Ranitidine, Raticina, Ranix, Coralen, Randin, Apozan, Raniogas, Gastrosedol, Ranuber, Ranitab, Zantac, Azantac, Ranial, Ranitin, Rantin, Ulsal, Galidrin, Ezopta, Lydin, Histac, Histak, Trigger, Quantor, Weichilin, Zantic, Xanidine, AH 19065, Achedos, Aciloc, Rani 2, Antagonin, Ranidil, Ranitidine hydrochloride (AH19065), Ranigast, Acloral, Melfax, Aldin, Neoceptin R, Ranidine, Raniplex, Ranitiget, Simetac, Sostril, Radinat, Ranimex, Ranital, AH 19065AB, 1,1-Ethenediamine, N'-[2-[[[5-[(dimethylamino)methyl]-2-furanyl]methyl]thio]ethyl]-N-methyl-2-nitro-, hydrochloride (1:1), Ranacid, Rantac, Ranitidine-akri, Raniben, Verlost, Zinetac, Consec
IUPAC Name	1-N'-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine;hydrochloride
Molecular Weight	350.86
Molecular Formula	C13H22N4O3S.ClH
Canonical SMILES	Cl.CNC(=C[N+](=O)[O-])NCCSCc1oc(CN(C)C)cc1
InChI	InChI=1S/C13H22N4O3S.ClH/c1-14-13(9-17(18)19)15-6-7-21-10-12-5-4-11(20-12)8-16(2)3
InChI Key	GGWBHVILAJZWKJ-CHHCPSLASA-N

Description	United States Pharmacopeia (USP) Reference Standard
Accurate Mass	350.1179
Form	neat
Format	Neat
Grade	secondary reference material (pharmaceutical)
Size	200MG

* Products or Services Interested: Ranitidine Hydrochloride (66357-59-3)
* Your question
* Name
* Email
Verification Code

CAT	Size	Shipping	Storage Conditions	Description	Price
APS66357593-1	100MG	Room Temperature	2-8°C Fridge/Coldroom	API Family: Matrix - API Family See respective official monograph(s); Product Type: API; Subcategory: British Pharmacopoeia	Inquiry
APS66357593-2	100MG	+20°C	+4°C	Subcategory: Pharmaceutical and veterinary compounds and metabolites	Inquiry
APS66357593-3	100MG	Room Temperature	2-8°C Fridge/Coldroom	API Family: Matrix - API Family See respective official monograph(s); Product Type: API; Subcategory: European Pharmacopoeia (Ph. Eur.)	Inquiry
APS66357593-4	250MG	Room Temperature	+5°C	API Family: Matrix - API Family Ranitidine Hydrochloride; Product Type: API; Subcategory: Mikromol, Additional pharmaceutical toxicology reference materials, API standards	Inquiry
APS66357593-5	10G	Room Temperature	-20°C	Subcategory: Enzyme inhibitors	Inquiry

Case Study

Ranitidine Hydrochloride Used for Solubility Optimization in Binary and Ternary Co-solvent Systems

Soleymani, Jafar, et al. Journal of Molecular Liquids 182 (2013): 91-94.

Ranitidine hydrochloride, a histamine H₂-receptor antagonist, was investigated for its solubility behavior in various binary and ternary solvent mixtures, including ethanol (EtOH), polyethylene glycol 200/400 (PEG 200/400), and 1,2-propanediol (PG), at 25 °C. The study aimed to determine optimal solvent systems for enhancing solubility, which is critical for formulation strategies such as soft gel encapsulation.
Experimental solubility data were fitted using the Jouyban-Acree model, yielding low mean percentage deviations (MPD), indicating high model reliability. Among all systems studied, PG exhibited the highest solubilizing capacity for Ranitidine HCl, while EtOH showed the lowest. In ternary EtOH-PG-PEG 400 mixtures, the solubility was notably influenced by the proportion of PG, suggesting its dominant role in solubilization. The PEG 200-EtOH system showed a peak solubility at a PEG 200 mass fraction of 0.80, while PEG 400-EtOH exhibited increased solubility up to 0.30 mass fraction of EtOH.
The study also confirmed that 72 hours was sufficient to achieve equilibrium in the saturated solutions. Differential Scanning Calorimetry (DSC) analysis of precipitated Ranitidine HCl from EtOH revealed the presence of polymorphic form II (~150 °C melting point), highlighting the impact of solvent environment on solid-state form.
This work supports the application of Ranitidine HCl in solubility studies and formulation development, particularly where aqueous systems are unsuitable.

Ranitidine HCl Used for the Preparation of Sustained-Release Gastric Buoyant Microsponges

Jafar, Mohammed, et al. Journal of Drug Delivery Science and Technology 55 (2020): 101453.

Ranitidine hydrochloride (Ranitidine HCl), a widely prescribed H₂-receptor antagonist for treating gastric ulcers, has been utilized in the development of sustained-release gastro-retentive microsponges to enhance its therapeutic efficacy and gastric residence time. In a recent study, Ranitidine HCl microsponges were successfully prepared using a xanthan gum (XG)-mediated double emulsion solvent evaporation method. Eudragit (EGT) served as the polymer matrix, with XG reinforcing the structural integrity and Tween 80 acting as an emulgent.
The optimized formulation, with an RTD:EGT ratio of 1:1, exhibited superior in vitro drug release (71.9% ± 2.79 over 12 h), production yield (81.3% ± 1.92), drug content (60.03% ± 1.81), and entrapment efficiency (68.2% ± 1.40). Scanning electron microscopy confirmed the successful formation of porous microsponge structures. In vitro tests demonstrated buoyant behavior and a biphasic release profile-an initial burst followed by controlled drug release under acidic conditions.
Importantly, in vivo anti-ulcer evaluations in an albino rat model revealed that the microsponge formulation provided enhanced mucosal protection and healing compared to pure Ranitidine HCl. These findings underscore the potential of gastric buoyant microsponge systems to improve the pharmacological performance of Ranitidine HCl, particularly for chronic ulcer therapy, offering controlled release and targeted gastric delivery.